Royalty Pharma reported double-digit top-line growth in 2025, driven by both existing royalties and newly acquired deals. The company highlighted robust revenue expansion across its diversified portfolio of biopharmaceutical assets.

In late 2025, Royalty Pharma completed the internalization of its external manager, bringing asset management in-house. This strategic shift is expected to eliminate external management fees and streamline decision-making.

For 2026, management forecasted mid-single-digit growth in recurring royalty receipts, reflecting deal timing and portfolio maturation. The outlook underscores a focus on steady, sustainable revenue increases rather than one-time gains.